PMID: 6548970
MEDVi highlights that 93% of its patients keep the weight off after initial loss, provided they remain consistent with treatment and follow the care plan
Antibodies against PARP (ab191217), Caspase-9 (ab32539), Cyclin D1 (ab40754), CDK6 (ab124821), p21 (ab109520), Cyclin A2 (ab32386), Cyclin E1 (ab33911), ASNS (ab40850), GPX4 (ab125066), Ferritin (ab75973), TfR1 (ab214039), IREB2 (ab232994), RRM2 (ab57653), c-Myc (ab32072), NDUFV2 (ab183715), NDUFS3 (ab177471), NDUFS8 (ab170936), Grim19 (ab110240), SDHA (ab137040), SDHB (ab178423), UQCRB (ab190360), UQCRC2 (ab203832), UQCRFS1 (ab191079), COX IV (ab202554), ATP5A (ab176569), and TOMM20 (ab186735) were obtained from Abcam (Cambridge, MA)
Kido J, Haberle J, Sugawara K, Tanaka T, Nagao M, Sawada T, et al
doi: 10.1093/ajcn/77.6.1352 32